BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11863117)

  • 1. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Blanke CD; Shultz J; Cox J; Modiano M; Isaacs R; Kasimis B; Schilsky R; Fleagle J; Moore M; Kemeny N; Carlin D; Hammershaimb L; Haller D
    Ann Oncol; 2002 Jan; 13(1):87-91. PubMed ID: 11863117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
    Punt CJ; Keizer HJ; Douma J; Skovsgaard T; Schüller J; Muller EW; Ten Napel CH; Croles JJ; Lochs H; Zhang J; Hammershaimb L
    Ann Oncol; 2002 Jan; 13(1):81-6. PubMed ID: 11865814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
    Punt CJ; Blanke CD; Zhang J; Hammershaimb L
    Ann Oncol; 2002 Jan; 13(1):92-4. PubMed ID: 11865815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Conti JA; Kemeny N; Seiter K; Goker E; Tong W; André M; Ragusa K; Bertino JR
    J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD; Messenger M; Taplin SC
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
    Machiavelli MR; Salum G; Pérez JE; Ortiz EH; Romero AO; Bologna F; Vallejo CT; Lacava JA; Dominguez ME; Leone BA
    Am J Clin Oncol; 2004 Apr; 27(2):149-54. PubMed ID: 15057154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H; Hohenberger P; Lochs H; Haboubi N; Berdel WE; Thiel E; Kreuser ED
    Oncology; 2000 May; 58(4):273-9. PubMed ID: 10838491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
    Comella P; De Vita F; Mancarella S; De Lucia L; Biglietto M; Casaretti R; Farris A; Ianniello GP; Lorusso V; Avallone A; Cartenì G; Leo SS; Catalano G; De Lena M; Comella G
    Ann Oncol; 2000 Oct; 11(10):1323-33. PubMed ID: 11106123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Fuchs CS; Marshall J; Mitchell E; Wierzbicki R; Ganju V; Jeffery M; Schulz J; Richards D; Soufi-Mahjoubi R; Wang B; Barrueco J
    J Clin Oncol; 2007 Oct; 25(30):4779-86. PubMed ID: 17947725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B; Luis R; Jaime M; Franceschi D
    Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
    Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
    Borner MM; Castiglione M; Bacchi M; Weber W; Herrmann R; Fey MF; Pagani O; Leyvraz S; Morant R; Pestalozzi B; Hanselmann S; Goldhirsch A
    Ann Oncol; 1998 May; 9(5):535-41. PubMed ID: 9653495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
    Garcia AA; Leichman L; Baranda J; Pandit L; Lenz HJ; Leichman CG
    Int J Gastrointest Cancer; 2003; 34(2-3):79-86. PubMed ID: 15361639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E
    Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
    Hudes GR; LaCreta F; DeLap RJ; Grillo-Lopez AJ; Catalano R; Comis RL
    Cancer Chemother Pharmacol; 1989; 24(2):117-22. PubMed ID: 2525077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
    Hausmaninger H; Moser R; Samonigg H; Mlineritsch B; Schmidt H; Pecherstorfer M; Fridrik M; Kopf C; Nitsche D; Kaider A; Ludwig H
    Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.